MET and malignant colon neoplasm: In this study, we demonstrated that MET activation induced by cetuximab was responsible for cetuximab resistance in colon cancer cells, indicating the benefits of MET inhibition as a novel therapeutic strategy to overcome MET-driven resistance in the clinic.